NCT04386967View on ClinicalTrials.gov

OH2 Injection in Solid Tumors

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

November 22, 2018

Primary Completion Date

March 13, 2026

Study Completion Date

December 13, 2026

Conditions
Solid TumorMelanoma
Interventions
BIOLOGICAL

OH2 injection

Oncolytic Type 2 Herpes Simplex Virus

DRUG

Keytruda

Anti-PD-1 antibody

Trial Locations (1)

100010

RECRUITING

Peking University Cancer Hospital, Beijing

Sponsors
All Listed Sponsors
lead

Binhui Biopharmaceutical Co., Ltd.

INDUSTRY